UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of June 2018
Commission File No.:001-38367

SOL-GEL TECHNOLOGIES LTD.

(Translation of registrant's name into English)

7 Golda Meir Street
Ness Ziona 7403650, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Attached hereto and incorporated by reference herein is a copy of the presentation to be made by the Company at the Jefferies 2018 Global Healthcare Conference held in New York.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOL-GEL TECHNOLOGIES LTD.

Date: June 6, 2018

By: /s/ Gilad Mamlok
Gilad Mamlok
Chief Financial Officer

Sol-Gel

Advanced Topical Therapy

NASDAQ: SLGL

Cautionary Note on Forward-Looking Statements

This document contains forward-looking statements of Sol-Gel Technologies Ltd. (the 'COMPANY'). All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the COMPANY'S actual results, performance or achievements to be materially different from any future results, performance or achievements express or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. the COMPANY has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the COMPANY'S business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond the COMPANY'S control. The events and circumstances reflected in the COMPANY'S forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the COMPANY operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the COMPANY may face. Except as required by applicable law, the COMPANY does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This presentation is not an offer to sell securities of the COMPANY and it is not soliciting offers to buy securities of the COMPANY in any jurisdiction where the offer or sale is not permitted.

This presentation concerns product candidates that are or have been under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authorities. These product candidates are currently limited by U.S. Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

Our Dermatology Company

- Branded and generic clinical-stage pipelines of topical drugs
- Proprietary microencapsulation delivery system
- Phase II clinical data on three branded drug product candidates
- Four collaborations on generic products with 50/50 gross profit sharing
- Tentative approval for our 1st generic drug product
- Near-term news flow
- Successful track record

Our Branded and Generic Pipelines



Common Indications Requiring Better Therapies

Acne Vulgaris

- A disease of the pilosebaceous unit, involving abnormalities in sebum production, follicular epithelial desquamation, bacterial proliferation and inflammation
- Benzoyl peroxide, tretinoin, adapalene and topical antibiotics are the mainstay of acne therapies
- ~$2.7 billion sales in the U.S. in 2017 of topical Rx drugs, of which fixed-dose combination drugs account for ~$900 million
- Sales of tretinoin are x5 the sales of adapalene, but no tretinoin/benzoyl peroxide combination is currently available

Subtype II Rosacea

- A chronic, inflammatory skin condition that most often affects the face
- ~$395 million sales in the U.S. in 2017 of topical products: Soolantra®, Finacea® and generic metronidazole
- Poor adherence to current drugs

Sources: IQVIA (IMS) for year ending December 2017; L.E.K. study (2017)

Our Branded Drug Product Candidates

TWIN (acne vulgaris)	▪ **Designed to be a highly effective treatment for acne vulgaris by combining benzoyl peroxide and tretinoin** ▪ Major challenges were the instability of tretinoin in the presence of benzoyl peroxide and irritation ▪ Encapsulation allows stabilization and is also expected to contribute to patient compliance
SIRS-T (acne vulgaris)	▪ **Designed to be the preferred tretinoin treatment for acne vulgaris** ▪ Common side effects of tretinoin include itching, redness, swelling, dryness, peeling and scaling ▪ Encapsulation was designed to reduce irritation and is therefore expected to contribute to patient compliance
Epsolay® (subtype II rosacea)	▪ **Encapsulated benzoyl peroxide, designed to be a new standard of care for subtype II rosacea** ▪ Benzoyl peroxide is an oxidizing agent that successfully treats inflamed lesions but cannot be well-tolerated by rosacea patients ▪ Encapsulation was designed to reduce irritation and is expected to contribute to patient compliance

Our Microencapsulation Platform

Encapsulated tretinoin microcapsule



Encapsulated tretinoin crystals inside broken microcapsule



SEM pictures of our silica-based encapsulated tretinoin

TWIN Phase II Co-Primary Efficacy Results (ITT)

Success in Dichotomized IGA at Week 12

	Vehicle	TWIN Low	TWIN High	E-ATRA Low	E-ATRA High	E-BPO
P-value vs. vehicle		*0.006*	*<0.001*	*0.015*	*0.001*	
	12.3%	*27.4%*	*39.7%*	*24.9%*	*31.7%*	*22.1%*
	N=115	N=116	N=117	N=118	N=118	N=118



Inflammatory Lesion Mean Absolute Change from Baseline at Week 12

	Vehicle	TWIN Low	TWIN High	E-ATRA Low	E-ATRA High	E-BPO
	(11.5)	*(17.0)*	*(16.9)*	*(13.9)*	*(14.9)*	*(13.8)*
P-value vs. vehicle		*<0.001*	*<0.001*	*0.060*	*0.003*	



Non-Inflammatory Lesion Mean Absolute Change from Baseline at Week 12

	Vehicle	TWIN Low	TWIN High	E-ATRA Low	E-ATRA High	E-BPO
	(13.7)	*(23.7)*	*(23.6)*	*(17.8)*	*(23.8)*	*(16.2)*
P-value vs. vehicle		*<0.001*	*<0.001*	*0.002*	*<0.001*	



SIRS-T Supportive Clinical Results (ITT)

Success in Dichotomized IGA at Week 12

P-value vs. vehicle		*0.015*	*0.001*



Inflammatory Lesion Mean Percent Change from Baseline at Week 12



P-value vs. vehicle		*0.060*	*0.003*

Non-Inflammatory Lesion Mean Percent Change from Baseline at Week 12



P-value vs. vehicle		*0.002*	*<0.001*

Epsolay® Phase II Co-Primary Efficacy Results (ITT)

Success in Dichotomized IGA at Week 12

P-value vs. vehicle *0.0013*

- The FDA required a modification to our definition of "clear" on the IGA scale such that the category of "clear" represented the absence of the disease
- Out of the 11 subjects that were defined as "mild" at baseline, there was only one subject that was treated with Epsolay® 5% and reached "clear" at the end of the trial



Inflammatory Lesion Count – Change from Baseline at Week 12



Other Acne Trial Results(‡) – Moderate Patients (ITT)

Number of Patients	Severe	0	0	1
	Moderate	102	108	1,043
	Mild	0	0	0
Baseline # Lesions	Inflam.	25.9	29.7	28.8
	Non-inflam.	42.1	53.7	46.9
Daily Dose[3]		QD	QD	QD

Note (‡): Sol-Gel did not conduct a head-to-head comparison trial or study. The results described above are for illustrative purposes only and should not be construed as conclusions to be drawn if we did conduct a head-to-head comparison trial or study

Other Subtype II Rosacea Trial Results(‡) (ITT)

Number of Patients	Severe	5	82	113	26	65	0	52	48
	Moderate	21	369	346	172	418	557	67	77
	Mild	4	0	0	0	0	0	8	17
Baseline # Inflammatory lesions		22.9	31.0	33.3	21.6	21.7	18.3	19.5	20.5
Daily Dose[1]		QD	QD	QD	QD	QD	QD	QD	QD

Notes: (1) "clear" definition: "no inflammatory lesions present with no or very mild erythema immediately localized to and around where inflammatory lesions were present"
(2) Most subjects had "moderate" rosacea at baseline. 10-week study
(3) 16-week study

Note (‡): Sol-Gel did not conduct a head-to-head comparison trial or study. The results described above are for illustrative purposes only and should not be construed as conclusions to be drawn if we did conduct a head-to-head comparison trial or study

Our Upcoming Phase III Pivotal Trials

Epsolay®

- SPA request was submitted and we have an agreement in place on the study design
- Each pivotal trial is planned to enroll 350 subjects in a 2:1 ratio of Epsolay® 5% vs. vehicle, with a power > 99%
- Pivotal trials are planned to be initiated in H1/2018 with readouts in 2019

TWIN

- End-of-Phase II meeting was held
- Pivotal trials are to be initiated as planned in H2/2018 with readouts in H2/2019

Our Generic Pipeline

Broad Pipeline	▪ Six generic drug candidates in our pipeline; some are being developed before the reference listed drug (RLD) is approved; one received tentative approval
Multiple Partnerships	▪ Three of our generic drug product candidates are being developed in collaboration with Perrigo and one with Douglas Pharmaceuticals
Profitable Contracts	▪ In all these collaborations we share development costs with our partner and we will share the gross profit 50/50
First Success Achieved	▪ Our Paragraph IV ANDA for ivermectin cream, 1%, received tentative approval from the FDA
Near-Term News Flow	▪ We plan to initiate a bioequivalence study regarding another generic drug candidate in H2/2018

Financial Profile

- Gross proceeds of $86.3 million raised in IPO of 7,187,500 ordinary shares on February 5, 2018
- 18,949,968 shares outstanding as of March 31, 2018
- $83.8 million of cash, cash equivalents and deposits as of March 31, 2018
- Cash runway expected to be sufficient to fund Phase III clinical programs for TWIN and Epsolay® and a bioequivalence study

Recent Milestones and Next Steps

2017

- [x] Reported positive results from TWIN Phase II trial in acne vulgaris
- [x] Had an EOPII meeting with the FDA about Epsolay®
- [x] Submitted a Paragraph IV ANDA, for ivermectin cream, 1% (sponsored by Perrigo)

2018

- [x] Obtained tentative approval of ANDA for ivermectin cream, 1% (sponsored by Perrigo)
- [x] Had an EoPII meeting with the FDA about TWIN
- [ ] Plans to initiate TWIN Phase III program in acne vulgaris in H2 2018
- [ ] Plans to initiate Epsolay® Phase III program in subtype II rosacea in H1 2018
- [ ] Plans to initiate bioequivalence study for a generic drug candidate
- [ ] Plans to hire U.S. commercialization leader for the launches of TWIN and Epsolay®

2019

- [ ] Plans to report Phase III results for TWIN in acne vulgaris
- [ ] Plans to report Phase III results for Epsolay® in subtype II rosacea
- [ ] Plans to complete preparation and scale-up for Phase III clinical trials for SIRS-T
- [ ] Plans to report bioequivalence study results regarding a generic drug candidate

For further information
please contact alon.seri-levy@sol-gel.com